Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Period	dileps
2020-12-31	-$4.15
2021-12-31	-$3.40
2022-12-31	-$2.60
2023-12-31	-$1.77
2024-12-31	-$1.01

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANNX	$6.08	+1.50%	1.54M
3
4
5

Annexon Inc. (ANNX) Earnings Per Share (EPS)

EPS (Earnings Per Share) Data

Get Annexon Inc. Data in Excel

More ANNX Financial Data